More than 40 million Americans and 90 million Europeans live with stress urinary incontinence, a condition that often leads to depression and social stigma.

Ajax Health is making a $60 million investment in UroMems, a developer of the first smart automated artificial urinary sphincter implant, to position the device as a new standard of care.

UroMems' UroActive System is a MyoElectroMechanical System placed around the urethral duct that automatically adjusts based on patient activity, eliminating manual adjustments.

The device is being studied for both men and women.

The company, co-founded by CEO Hamid Lamraoui, is currently enrolling the SOPHIA2 pivotal clinical trial across 21 centers in the U.S.

The new capital will fund the trial through completion and prepare data packages for FDA premarket approval and European market submissions.

The investment was made from Ajax Health Fund I, a vehicle sponsored by ICONIQ and sub-advised by medtech-focused investment firm Ajax Health.

Ajax partner David Beylik and senior vice president of medical affairs Dr.

Jeremy Durack, a practicing interventional radiologist, are joining the UroMems board.

Beylik cited the firm's model of partnering with potential industry leaders to help build and scale device organizations.

The round follows a $47 million Series C completed in June 2024 led by Crédit Mutuel Innovation with participation from the European Innovation Council, Wellington Partners, Bpifrance, Supernova Invest, Hil-Invent, b-to-v Partners, and Financière Arbevel.

Those existing investors remain alongside Ajax Health, with Bpifrance and Wellington Partners expressing confidence in the technology's potential to disrupt the SUI market.